Treatment options for relapsed small-cell lung cancer

@article{Azim2007TreatmentOF,
  title={Treatment options for relapsed small-cell lung cancer},
  author={Hatem A Azim and Apar Kishor Ganti},
  journal={Anti-Cancer Drugs},
  year={2007},
  volume={18},
  pages={255-261}
}
Small-cell lung cancer is a chemo-sensitive disease with a response rate ranging from 70 to 90% for first-line treatment; however, relapses are very common and as a result long-term survival is poor. Chemotherapy has demonstrated a benefit over the best supportive care, even in patients who have relapsed after initial treatment with a platinum-based regimen. Agents currently being used in salvage therapy include topotecan, cyclophosphamide, doxorubicin and vincristine regimen. In the last 5… Expand
New Agents for Treatment of Recurrent Small-Cell Cancer: Tumor-Specific Abnormal Vasopressin V2 Receptor Antibodies
TLDR
This mouse anti-AbnR2 antibody was found to reduce the growth of SCLC xenografts representing recurrent disease in nu/nu mice, and to have synergistic, tumor anti-proliferative effects when used with cyclophosphamide, but not cisplatin, in completely inhibiting growth. Expand
Emerging role of phytochemicals in targeting predictive, prognostic, and diagnostic biomarkers of lung cancer.
  • Jyoti D Singh, Suaib Luqman, A. Meena
  • Medicine
  • Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • 2020
TLDR
Present review provides comprehensive information about available lung-cancer biomarkers under the classification of predictive, prognostic, and diagnostic type, and discusses and enlists phytochemicals with mode of action in different biomarkers. Expand
Clinical development of new formulations of cytotoxics in solid tumors
TLDR
Improvement in drug development strategies and the appreciation of the mechanisms of action and resistance of the cytotoxic agents currently available in the clinic open the door for developing agents that have the potential of improving clinical outcomes with better safety profiles. Expand
Intricatinol synergistically enhances the anticancerous activity of cisplatin in human A549 cells via p38 MAPK/p53 signalling
TLDR
Intricatinol has a selective anticancer potential and could synergize cytotoxicity of CIS and the combination of INT and CIS may serve as an effective anticancer strategy for the treatment of non-small cell lung carcinoma. Expand
Growth Impairment of Small-Cell Cancer by Targeting Pro-Vasopressin with MAG-1 Antibody
TLDR
Evidence is provided that the growth rate of SCLC tumors can be extensively reduced by treatment with MAG-1 antibody, and that a humanized form of this antibody could, in future, be potentially used for targeting therapy onto recurrent SclC in patients. Expand
Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy
TLDR
Elevated serum concentration of soluble programmed cell death ligand 1 might be an independent risk factor for non-response to chemotherapy and cancer caused death in small cell lung cancer patients. Expand
Are there new therapeutic options for treating lung cancer based on herbal medicines and their metabolites?
TLDR
It is suggested that herbal medicines and phytochemicals can be useful anti-cancer agents for lung cancer treatment by targeting molecular signaling involved in the regulation of angiogenesis, metastasis and severe side effects, only provided quality control and reproducibility issues were solved. Expand
Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC).
TLDR
Results of the current study suggest that isorhamnetin combinations with cisplatin and carboplatin might be a potential clinical chemotherapeutic approach for NSCLC. Expand
Anti-proliferation and anti-metastasis effect of barbaloin in non-small cell lung cancer via inactivating p38MAPK/Cdc25B/Hsp27 pathway.
TLDR
Research indicated that barbaloin inhibited the proliferation and metastasis of NSCLC cells in vivo and in–vitro, which may provide safer and more effective aspects for the treatment ofNSCLC. Expand
Dual or multi-targeting inhibitors: The next generation anticancer agents.
TLDR
Current review focus on the discoveries of dual targeting agents in cancer therapy using rational, computational, proteomic, bioinformatics and polypharmacological approach that enables the discovery and rational design of effective and safe multi-target anticancer agents. Expand
...
1
2
...

References

SHOWING 1-10 OF 88 REFERENCES
VP-16 and cisplatin as first-line therapy for small-cell lung cancer.
TLDR
Results compare favorably with reports of standard induction chemotherapy regimens and provide further evidence of the activity of the VP-16 and cisplatin regimen in patients with SCLC. Expand
Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.
TLDR
This study demonstrates that CAV has limited activity following failure to respond to VPP, and identifies 29 patients who received CAV after their tumors failed to respond or relapsed after VPP or etoposide and carboplatin (VPC). Expand
Treatment of advanced non-small cell lung cancer: the Southwest Oncology Group experience.
TLDR
In extensive disease patients who are fully ambulatory, cisplatin based combinations have been shown to produce responses of up to 30% and probably exert modest beneficial effects on survival, Nonetheless, current therapies are suboptimal; better ways to use cisPlatin and other drugs are needed. Expand
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.
  • C. Rudin, G. Otterson, +6 authors E. Vokes
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2002
TLDR
It is demonstrated that G3139 can be combined with paclitaxel in a cytotoxic dose range, and suggests that a similar combination be tested for activity in the context of chemoresponsive disease. Expand
Phase II study of imatinib in patients with small cell lung cancer.
TLDR
There was no observed antitumor activity in this limited Phase II trial of patients with SCLC, of which only a few tumors showed expression of the imatinib target. Expand
Small cell lung cancer.
TLDR
Evidence-based guidelines for the staging and treatment of SCLC are outlined and it is suggested that patients achieving a complete remission should be offered prophylactic cranial irradiation. Expand
Chemotherapy versus best supportive care for extensive small cell lung cancer.
TLDR
Chemotherapeutic treatment prolongs survival in comparison with placebo in patients with advanced SCLC, and the impact of chemotherapy on quality of life and in patientsWith poor prognosis is unknown. Expand
Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study.
TLDR
The combination of paclitaxel and carboplatin is a relatively active and well-tolerated regimen as salvage treatment in patients with refractory SCLC. Expand
Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule.
  • H. Groen, E. Fokkema, +4 authors E. Smit
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
Second-line PC in CDE-resistant SCLC patients yields a high response rate and seems non-cross-resistant to CDE, and toxicity was mild in these poor-prognosis patients. Expand
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
TLDR
TPT at the dose and schedule used has modest antitumor activity in patients with small-cell lung cancer refractory to etoposide and cisplatin, which indicates that clinical resistance to the topoisomerase II poison etopOSide does not confer cross-sensitivity to thetopoisomersase I poison TPT. Expand
...
1
2
3
4
5
...